Showing 2061-2070 of 9336 results for "".
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. This approval is based on data from the…
- FDA Approves New Dupixent Pre-filled Pen Designed to Support More Convenient Self-Administrationhttps://practicaldermatology.com/news/fda-approves-new-dupixent-pre-filled-pen-designed-to-support-more-convenient-self-administration/2460444/The FDA has approved a 300mg single-dose pre-filled pen for Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab). The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma, and …
- Acne News: Clascoterone Cream 1% Exhibits Long-Term Safety for Treatment of Acnehttps://practicaldermatology.com/news/acne-news-clascoterone-cream-1-exhibits-long-term-safety-for-treatment-of-acne/2460442/Cassiopea SpA’s Clascoterone cream 1% is safe for the treatment of acne with low rates of treatment-related adverse events, according to a study in the online issue of Journal of the American Academy of Dermatology (JAAD). Clascoterone is a topical androgen receptor inhibitor that fights acne by l…
- Cynosure Reopening Survey: If You Wear Masks, They Will Come Backhttps://practicaldermatology.com/news/cynosure-reopening-survey-if-you-wear-masks-they-will-come-back/2460441/Fully 85 percent of people plan to return to aesthetic treatments within 12 months of COVID-19 restrictions being lifted, and 63 percent plan to return to practices within just three months of restrictions being lifted in their respective countries, according to a new survey by Cynosure. The surve…
- Abbvie's RINVOQ Improves Skin Clearance and Itch in First Phase 3 Study for ADhttps://practicaldermatology.com/news/abbvies-rinvoq-improves-skin-clearance-and-itch-in-first-phase-3-study-for-ad/2460439/AbbVie’s RINVOQ (upadacitinib) performed well in Measure Up 1, the first Phase 3 study to evaluate its efficacy and safety for the treatment of moderate-to-severe atopic dermatitis. Full results from Measure Up 1 will be presented at a future medical meeting and published in a peer-reviewed public…
- Label Update: Low Risk of Antibiotic Resistance with Almirall's Seysarahttps://practicaldermatology.com/news/label-update-low-risk-of-antibiotic-resistance-with-seysara/2460437/The FDA approved a label update for Almirall's Seysara stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline. This information is included in the Microbiology Section (12.4) of the prescribing information. Seysara is a novel tetracycline-derived…
- Physician-Created App Unveils Remote Check-In Feature to Prevent Spread of COVID-19 in Medical Practiceshttps://practicaldermatology.com/news/physician-created-app-unveils-remote-check-in-feature-to-prevent-spread-of-covid-19-in-medical-practices/2460436/DocClocker, an app that allows patients to receive real-time wait time reporting of their medical providers, enabling patients to avoid long waits in medical waiting rooms—limiting COVID-19 exposure risks. The company recently launched a new feature for the app—DocClocker Remote Check-In. In the w…
- Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for Atopic Dermatitishttps://practicaldermatology.com/news/secondary-efficacy-and-patient-reported-outcomes-in-phase-2b-clinical-trial-of-tapinarof-cream-for-atopic-dermatitis/2460435/Secondary efficacy and patient-reported outcomes from Dermavant's Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis were recently reported in The Journal of the American Academy of Dermatology (JAAD). Tapinarof cream is a potential first-in-class, once-dai…
- AAD Survey: Parents Get the Importance of Sunscreen for their Kidshttps://practicaldermatology.com/news/aad-survey-parents-get-the-importance-of-sunscreen-for-their-kids/2460433/Fully 74 percent of parents today worry about sun protection more with their children than their parents did with them, and 90 percent of parents believe it’s important to teach their children healthy habits now so they will keep them when they are adults, finds a new survey from the American Acade…
- New Phase 3 Data for Tremfya Show Consistent, High Levels of Skin Clearance Through Four Years in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-phase-3-data-for-tremfya-show-consistent-high-levels-of-skin-clearance-through-four-years-in-moderate-to-severe-plaque-psoriasis/2460431/New long-term plaque psoriasis data for The Janssen Pharmaceutical Companies of Johnson & Johnson's Tremfya (guselkumab) show consistent, high levels of skin clearance at week 100 and week 204 (four years). In the open-label extension of VOYAGE 2, at four years, 80 percent of patients who were tre…